Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes

Inclusion Criteria:

• Informed consent obtained

• Body Mass Index (BMI) of 30.0 kg/m^2 or above

• Body Mass Index (BMI) of 27 kg/m^2 or above in the presence of co-morbidities oftreated or untreated dyslipidemia and/or hypertension

• Stable body weight

• Preceding failed dietary effort

Exclusion Criteria:

• Known type 1 or type 2 diabetes

• Glycosylated haemoglobin (HbA1c) of 6.5 % or above (Screening visit 1) or FPG of 126mg/dL (7 mmol/L) or above (Screening visit 2) or 2 hour post-challenge (OGTT) plasmaglucose of 200 mg/dL (11.1 mmol/L) or above (Screening visit 2)

• Screening calcitonin of 50 ng/L or above

• Family or personal history of multiple endocrine neoplasia type 2 (MEN2) or familialmedullary thyroid carcinoma (FMTC)

• Personal history of non-familial medullary thyroid carcinoma

• History of acute or chronic pancreatitis

• Obesity induced by drug treatment

• Use of approved weight lowering pharmacotherapy

• Previous surgical treatment of obesity

• History of major depressive disorder or suicide attempt

• Uncontrolled hypertension (systolic blood pressure of 160 mmHg or above and/ordiastolic blood pressure of 100 mmHg or above)